Physician profile
David G Ike
NPI 1033159678
$3,855.13
in general payments reported to CMS, 2019-2025
34 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $72.98 · 2021: $178 · 2022: $612 · 2023: $1,019 · 2024: $822 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $478.88 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $425.61 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $384.04 | 2019-2025 | |
| Atricure, INC. | $345.74 | 2022-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Abbott Laboratories | $266.40 | 2022-2024 | Optis, Pressurewire, Xience Skypoint |
| Abiomed | $240.31 | 2023-2025 | Impella |
| Inari Medical, INC. | $223.80 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $223.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $174.35 | 2021-2025 | Verquvo |
| Nuwellis, INC. | $168.62 | 2019 | |
| Cardiva Medical, INC. | $124.54 | 2022-2023 | Cardiva Vascade 6/7f Vcs |
| Alnylam Pharmaceuticals INC. | $124.34 | 2024-2025 | Onpattro |
| Amgen INC. | $114.93 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.06 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $66.39 | 2023-2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56.38 | 2021-2025 | Lokelma, Wainua |
| Kiniksa Pharmaceuticals, LTD. | $40.27 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $36.55 | 2019-2022 | |
| Heartflow, INC. | $29.21 | 2025 | |
| Cvrx, INC. | $27.55 | 2023-2024 | Barostim Neo System |
| Recor Medical INC | $25.38 | 2024 | Paradise Renal Denervation System |
| Daiichi Sankyo INC. | $25.28 | 2023 | Injectafer |
| Philips North America LLC | $22.26 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $22.24 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $20.70 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kestra Medical Technology Services, INC. | $17.89 | 2024 | Assure Wcd |
| Novo Nordisk INC | $16.44 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $15.34 | 2022 | |
| Cardinal Health 200 LLC | $14.66 | 2019 | |
| Chiesi USA, INC. | $14.44 | 2021 | |
| Janssen Scientific Affairs, LLC | $14.12 | 2019 | |
| Scpharmaceuticals INC. | $13.92 | 2025 | |
| Cardiovascular Systems INC. | $10.11 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.